Visomitin, eye drops 5 ml

Vizomitin has a keratoprotective effect.

Pharmacodynamics

Plastoquinoyldecyltriphenylphosphonium bromide (PDTP) is a derivative of plastoquinone, which is linked to the triphenylphosphine residue through the linker chain (C10). PDTF in low (nanomolar) concentrations exhibits high antioxidant activity.

It also stimulates the process of tear production, epithelization and promotes the increase in tear film stability. According to data of a clinical research, in patients with age-related cataract the preparation protects the eye tissue from oxidative damage by increasing antioxidant activity of the tear and improves visual acuity.

Pharmacokinetics

Pharmacokinetics studies in humans have not been conducted. In preclinical animal studies, distribution of PDTF in organs and tissues occurred within 48 h after intravenous and intragastric administration.

PDTF was found to be present in the highest concentrations in kidney, liver and heart tissues within 1 h of administration. PDTF is relatively rapidly subjected to enzymatic cleavage and covalent binding to proteins.

Indications

Dry eye syndrome, age-related cataracts (to slow down the progression of the disease, in order to delay surgical intervention).

Active ingredient

Composition

1 ml of eye drops contains:

the active ingredient:

Plastoquinonildecyltriphenylphosphonium bromide 0.155 µg,

excipients:

benzalkonium chloride, 0.1 mg;

hypromellose, 2 mg;

sodium chloride – 9 mg;

sodium dihydrophosphate – 0.81 mg;

sodium hydrophosphate dodecahydrate – 1.16 mg;

Sodium hydroxide 1M solution – to pH 6.3-7.3;

water for injection – up to 1 ml

How to take, the dosage

Topically (into the conjunctival sac). 1-2 drops of the drug 3 times a day.

Duration of treatment course is determined by the doctor depending on the severity of symptoms.

The use of the drug in therapy of age-related cataract should be conducted under supervision of a physician who should regularly monitor the patient’s condition in order to assess the need for surgical intervention depending on the progression of the disease.

In a clinical trial, the use of the drug was continued for 6 months.

Interaction

If necessary, it can be used simultaneously with other eye drops.

A minimum of 5 minutes between instillations.

Special Instructions

Impact on the ability to drive vehicles and mechanisms.

If after using the drug short-term blurred vision occurs, it is not recommended to drive vehicles and engage in activities requiring increased concentration until its recovery.

Contraindications

Side effects

Allergic reactions.

Sensory organs: brief burning and stinging sensation in the eyes after injection is possible.

Pregnancy use

Adequate controlled studies in pregnant and breastfeeding women have not been conducted.

It is not recommended to prescribe the drug during pregnancy.

Breastfeeding should be discontinued if it is necessary to prescribe during lactation for the period of treatment.